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In addition to their well known control of reproduc-
tive functions, estrogens modulate important
physiological processes. The identification of com-
pounds with tissue-selective activity will lead to
new drugs mimicking the beneficial effects of es-
trogen on the prevention of osteoporosis and car-
diovascular or neurodegenerative diseases, while
avoiding its detrimental proliferative effects. As an
innovative model for the in vivo identification of
new selective estrogen receptor modulators
(SERMs), we engineered a mouse genome to ex-
press a luciferase reporter gene ubiquitously. The
constructs for transgenesis consist of the reporter
gene driven by a dimerized estrogen-responsive
element (ERE) and a minimal promoter. Insulator
sequences, either matrix attachment region (MAR)
or b-globin hypersensitive site 4 (HS4), flank the
construct to achieve a generalized, hormone-
responsive luciferase expression. In the mouse we
generated, the reporter expression is detectable in
all 26 tissues examined, but is induced by 17b-
estradiol (E2) only in 15 of them, all expressing
estrogen receptors (ERs). Immunohistochemical
studies show that in the mouse uterus, luciferase
and ERs colocalize. In primary cultures of bone
marrow cells explanted from the transgenic mice
and in vivo, luciferase activity accumulates with
increasing E2 concentration. E2 activity is blocked
by the ER full antagonist ICI 182,780. Tamoxifen
shows partial agonist activity in liver and bone
when administered to the animals. In the mouse
system here illustrated, by biochemical, immuno-
histochemical, and pharmacological criteria, lucif-
erase content reflects ER transcriptional activity
and thus represents a novel system for the study of
ER dynamics during physiological fluctuations of
estrogen and for the identification of SERMs or
endocrine disruptors. (Molecular Endocrinology
15: 1104–1113, 2001
INTRODUCTION
In the last decade, the use of molecular tools provided
an insight on the previously unsought number of phys-
iological functions of estrogens in mammals and on
the complexity of their actions in target cells. In addi-
tion to having an impact on the knowledge of the
intracellular receptor mechanisms, these findings led
to a revision of the use of estrogens as therapeutic
agents (1). At the present time, molecules active
through estrogen receptors (ERs) are used in fertility
control, endocrine dysfunction, and cancer therapy. In
postmenopausal women, estrogen replacement ther-
apy (2) was proven efficacious for the prevention of
osteoporosis (3), and several lines of study suggested
that 17b-estradiol (E2) has beneficial effects in cardio-
vascular (4, 5) and selected neurodegenerative dis-
eases (6). Unfortunately, the prolonged use of this
hormone has been associated with increased risk of
breast and uterine cancer (7). The discovery that syn-
thetic ligands of the ER may exhibit tissue-specific
agonist or antagonist activity raised a new interest in
the use of these compounds for estrogen replacement
therapy (8, 9). These selective estrogen receptor mod-
ulators or SERMs are identified by comparative
screening in cells of different origin to characterize
their tissue-specific profile (agonist/antagonist). Gen-
erally, the study is carried out in transformed cell lines
stably or transiently transfected with ERa or -b and a
reporter of the receptor’s activated state. In addition to
limiting the analysis to a selected number of cells, this
method may also provide erroneous or defective re-
sults. In fact, the tissue-specific agonist/antagonist
activity of SERMs has been attributed to the presence
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of cell-specific proteins capable of interacting with the
hormone receptor complex (10), and these proteins
may be aberrantly expressed in cancer cells (11).
Thus, the major shortcoming of this screening proce-
dure is associated with the requirement of further in
vivo analysis for the identification of the pharmacody-
namic properties of the molecule to be developed. The
availability of an engineered mouse carrying an ER
reporter expressed ubiquitously as a transgene would
represent a remarkable advancement for the identifi-
cation and profiling of new SERMs. In addition, such a
model would be invaluable for the spatio-temporal
localization of ER activity and could provide data of
major impact for the full comprehension of estrogens
and ER functions from development to aging. Such an
experimental system can hardly be generated by clas-
sical transgenesis because of the difficulty in obtaining
a regulated expression of the transgene (12). To over-
come this limitation, we made use of insulator se-
quences previously described to oppose the interfer-
ence of the host genome on the expression of the
ectopic genes (13, 14).
In this study we describe a construct that led to
ubiquitous and estrogen-regulated expression of a re-
porter transgene. The transgenic mouse we generated
represents an innovative model for the study of the in
vivo dynamics of intracellular receptor activity.
RESULTS
Generation of the Constructs and Their
Preliminary Analysis in Stably Transfected Cells
The choice of luciferase as reporter gene was dictated
by several factors: 1) no protein structurally related to
this enzyme has been described in mammals; 2) the
assay for the quantitation of this enzymatic activity in
tissue homogenates is extremely sensitive; 3) very ef-
ficient antibodies are available for the localization of
the protein by immunohistochemistry. To obtain a
minimal constitutive and a strong estrogen-inducible
expression of the reporter, the arrangement of the
promoter cassettes was selected experimentally by
transient transfection studies in MCF-7, SK-N-BE, and
HeLa cell lines (not shown). A number of constructs
containing different deletion mutants of the minimal
promoter from the tk gene combined to different syn-
thetic multimers of the canonical estrogen-responsive
element (ERE), were assayed. The best arrangement
found consists of two palindromic EREs spaced 8 bp
apart located at 55 bp upstream from the tk promoter.
To limit position effects and gradual extinction of the
reporter expression (12), we generated constructs in
which the transgene was flanked by either the insula-
tors MAR (matrix attachment region) (15) or HS4 (b-
globin hypersensitive site 4) (16) (Fig. 1A). The effi-
ciency of these boundary elements was tested by
stable cotransfection of the constructs generated, and
the pSV2Neo vector in the ERa-positive MCF-7. 48
clones for each construct were isolated, expanded,
and tested for luciferase expression in the presence or
absence of 1 nM E2 (Fig. 1B). In the absence of hor-
mone, luciferase activity could be measured in 77%
(37/48) and 40% (19/48) of the cells transfected with
pHS4 and pMAR, respectively. In about 80% of these
(inducible clones), 16 h of E2 treatment caused a sig-
nificant increase in the reporter activity (at least 3-fold
over basal levels). When pERE was transfected, basal
luciferase activity could be detected only in 19% (9/48)
of the clones, and in 44% of these the enzymatic
activity was E2 inducible. Next, we evaluated the re-
lationship between the number of copies integrated
and luciferase expression in the absence or presence
of E2. In the absence of E2, linear correlation analysis
of the two variables produced lines of best fit with an
r coefficient of 0.66 for pHS4- and 0.79 for pMAR-
transfected clones. After 16 h of E2 induction, the r
calculated was 0.47 and 0.54 for the two groups of
clones. These values of r indicate a positive correlation
between the two variables analyzed, even though
Fig. 1. Insulator Activity in Stably Transfected MCF-7 Cells
A, Vectors used for the generation of stably transfected
cells. B, MCF-7 cells were cotransfected with pSV2Neo and
the indicated constructs. After selection, 48 single clones for
each transfected plasmid were isolated and expanded. Lu-
ciferase activity was measured in the absence or presence of
1 nM E2 for 16 h. Bars represent the percentage/total of
clones expressing detectable amounts of luciferase (upper
graph) or responsive to the hormonal treatment with at least
a 3-fold increase of luciferase activity over basal (lower
graph). The luciferase enzymatic activity was detected in two
separate experiments after triplicate treatment.
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these data most likely underestimate the insulator ac-
tivity because the clones in which transgene rear-
rangements had occurred were not eliminated from
the analysis.
These results are in agreement with previous studies
showing that insulators confer a copy dependency of
the transgene expression. In addition, here we show
that these sequences considerably facilitate the estro-
gen-regulated expression of the transgene in the chro-
mosomal context.
Effect of Insulators on Estrogen-Dependent
Transcription of the Reporter Gene in the Mouse
Linearized pMAR and pHS4 vectors deleted of plas-
mid sequences were microinjected into oocytes ex-
planted from C57Bl/6xDBA/2 F2 of mice zygotes. This
outbred strain was chosen to ensure a high efficiency
of transgenesis (17); furthermore, the presence of
C57BL/6 in the genetic background confers a good
responsiveness to estrogens (18, 19). Seventeen in-
dependent lines were obtained, but only 12 of these
were fertile, 9 carrying the pMAR and 3 carrying the
pHS4 construct. An initial screening for assessing
basal and estrogen-inducible expression of the lucif-
erase reporter was done by measuring the reporter
enzymatic activity in tissue homogenates from ovari-
ectomized mice of the F1 generation. Five organs were
initially taken into consideration: uterus, liver and brain
as well known targets for the hormone, and lung and
heart as negative controls. Table 1 shows that among
the lines that integrated the MAR transgene, three
showed an estrogen-inducible expression of the re-
porter in uterus, brain, liver, and lung. In line 31 the
hormone-inducible expression of the reporter was
found in uterus, liver, and brain, while in lines 56 and
59 it was restricted to brain. We did not detect any
basal or estrogen-inducible luciferase activity in the
heart. In lines 13 and 77, basal expression of the
reporter is low; however, treatment with E2 did not
result in its increase. In transgenic mice carrying the
HS4 construct, we observed very little expression of
the reporter in the organs investigated; only line 61
showed low basal and E2-induced expression of
luciferase.
Considering that minimal promoters are heavily in-
fluenced by position effects, we observed ectopical
expression of luciferase in only a few lines of mice;
we concluded that the presence of insulators allows
the position effects to be overcome without inter-
fering with the hormone-regulated expression of the
transgene.
Characterization of Estrogen-Dependent
Luciferase Expression in Transgenic Mice
A further characterization of the activity of the trans-
gene was carried out in line 2. Luciferase activity
was measured in 26 different tissues from 2-month-
old female mice, which had been ovariectomized 2
weeks before the experiment. To verify the capabil-
ity of E2 to induce the transgene transcription, mice
were treated for 16 h with either vehicle or E2 sub-
cutaneously. Figure 2A shows that in the absence of
hormonal stimulation a considerable level of lucif-
erase expression was found in tissues such as bone
marrow, brain, pituitary, liver, tongue, and mammary
gland, while in others the enzymatic activity found
was low, at the limit of detection. The hormonal
treatment induced an increase of the enzyme con-
tent higher than 5-fold with respect to controls in
liver, lung, spleen, bone marrow, brain, and thymus.
In eye, uterus, bladder, skin, adipocyte, and spinal
cord, the hormonal treatment resulted in an accu-
mulation of luciferase less remarkable (between 2.5-
and 4.9-fold over controls), but still clearly visible.
Finally, the treatment did not result in any change in
pancreas, tail, aorta, esophagus, thyroid, stomach,
blood, tongue, skeletal muscle, or heart (Fig. 2B).
When compared with the distribution of ERa and -b,
the distribution of luciferase activity indicated a
strict correlation between E2 responsiveness and
presence of the hormone receptors. Interestingly,
the lung, which was originally taken as a control
ER-negative organ, showed a high responsiveness
to the hormonal treatment. This finding is in line with
the recent report on the high content of ERb in lung (20).
Adjacent slices were stained with antibodies raised
against ERa or luciferase (Fig. 3). ERa immunoreac-
tivity was clearly detected in nuclei of cells in stroma,
endometrium, and glandular epithelium. Cytoplasmic
staining of luciferase was clearly visible in the same
cell types. In both cases, no staining was detected
when preimmune serum was used.
Table 1. Luciferase Expression in Transgenic Lines
pMAR pHS4
1 2 3 13 31 56 59 77 97 35 61 62
Uterus 1 1 2 n.i. 1/2 2 2 n.i. 2 2 1/2 2
Brain 1 1 1 n.i. 1 1 1 n.i. n.i. n.i. 1/2 2
Liver 1 1 2 2 1/2 2 2 n.i. 2 1/2 1/2 2
Lung 1 1 2 n.i. 2 2 2 n.i. 2 2 1/2 2
Heart 2 1/2 2 2 2 2 2 2 2 2 2 2
2, Below limits of detection; n.i., expressed, not inducible; 1/2, low level of expression, inducible; 1, high level of expression,
inducible.
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Bone Marrow Cells in Primary Culture Retain the
Estrogen-Inducible Luciferase Expression
Initial pharmacological characterization of the lucif-
erase expression was done in primary cultures of bone
marrow (Fig. 4). The cells were treated for 16 h with
increasing concentrations of E2 (0.01–10 nM) or with
100 nM of two ER antagonists: 4-hydroxytamoxifen (T)
and ICI 182,780 (ICI) alone or in the presence of 1 nM
E2. E2 induced a dose-dependent increase of lucif-
erase accumulation blocked by the presence of ICI
182,780. ICI 182,780 by itself did not produce any
effect. Conversely, 4-hydroxytamoxifen induced a sig-
nificant increase of luciferase levels even though lower
than E2 at the same concentration. In coadministration
with E2, 4-hydroxytamoxifen induced higher luciferase
accumulation, yet the level reached was still lower
than with E2 alone. This is compatible with the partial
agonist activity of 4-hydroxytamoxifen and with the
fact that it is present in the solution at a concentration
100-fold higher than E2. As control, we also tested
progesterone and dexamethasone (10 nM). Neither li-
gand had any effect on the ER reporter (Fig. 4).
Taken together, these data confirm that, even in
cells explanted from engineered mice, the transgene is
controlled by ligands of ER with modalities recapitu-
lating those reported for the natural target genes.
Pharmacological Modulation of Luciferase
Expression in Vivo
Two-month-old male mice were injected s.c. with 50
mg E2/kg and killed after 3, 6, or 16 h. As shown in Fig.
5 (upper panel) the maximal luciferase accumulation
was observed at 6 h after treatment both in liver and
bone tissues. When mice were treated for 6 h with
increasing concentrations of the hormone (Fig. 5, mid-
dle panel), the maximal effect on luciferase activity
was detected at 50 mg/kg. Interestingly, the adminis-
tration of 250 mg E2 /kg induced, in the bone, a lucif-
erase accumulation lower then with 50 mg/kg. Thus,
the luciferase accumulation is time and dose depen-
dent. Next, the effect of in vivo administration of the
two ER antagonists was investigated. Figure 5 (lower
panel) shows that the s.c administration of 250 mg
tamoxifen/kg for 6 h increased the level of luciferase in
liver and bone 12 times and 7 times, respectively,
confirming also in vivo the partial agonist activity of
tamoxifen in these tissues. The injection of 250 mg
tamoxifen/kg or ICI 182,780, 1 h before the adminis-
tration of 50 mg E2/kg, inhibited the E2-dependent
activation of luciferase expression as expected from
the antagonist effect of these compounds with respect
to E2.
DISCUSSION
We generated a transgenic mouse model for the study
of the dynamics of ER transcriptional activation in
primary tissue cultures and in vivo. Several lines of
evidence indicate that the model generated fulfills its
purpose: 1) E2 administration results in accumulation
of luciferase in organs and tissues reported to express
either or both of the two ER isoforms; 2) in uterus,
immunohistochemistry shows colocalization of lucif-
Fig. 2. Localization of Luciferase Activity in Mouse Tissues before and after E2 Treatment
Adult mice from transgenic line 2 were ovariectomized 2 weeks before treatment with E2 (50 mg/kg s.c. for 16 h) or vehicle
(vegetable oil). After animals were killed, tissues were rapidly removed, frozen, and kept at 280 C until assayed. Luciferase activity
measured in tissue extracts is expressed as relative luciferase units (RLU). A, Basal levels of luciferase activity. B, Ratio between
luciferase activity in estrogen-treated/control mice. The experiment was repeated three times with a total of six animals per group.
Bars are from a single, representative experiment.
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erase and ER immunoreactivity; 3) experiments in pri-
mary cultures of bone marrow show that luciferase
activity is controlled by E2 in a dose-dependent fash-
ion (with highest E2 activity compatible with its affinity
for the receptors) and ER antagonists display a profile
of activity in line with previous reports in vivo and in
vitro (21); 4) experiments in vivo show the dose- and
time dependency of E2 activity, the antagonist activity
of ICI 182,780, and the partial agonist activity of ta-
moxifen in bone and liver.
We believe that the key to the realization of our
model was the use of insulators. It is, in fact, well
known that the expression of transgenes driven by
weak promoters is heavily influenced by enhancers/
silencers surrounding the regions of insertion; in addi-
tion, methylation may gradually extinguish their tran-
scriptional activity. In the past, insulators have been
successfully used to counteract these effects in spe-
cific tissues. Here, we demonstrate that their use can
be extended to the achievement of the ubiquitous and
regulated expression of a given gene. Sixty percent of
the transgenic lines obtained expressed luciferase in
an estrogen-dependent fashion at least in some organ.
In-depth analysis of one positive line showed that in 26
target tissues, the expression of the transgene is cor-
rectly regulated after in vivo administration of E2. Yet,
in 40% of the mouse lines developed, the expression
of luciferase was either undetectable or not modulated
by E2.
This could be due to the use of a weak promoter,
which might have slightly restricted the possibility of
reaching detectable levels of reporter expression. The
E2-independent expression of luciferase may be as-
cribed to rearrangements of the vector during the in-
tegration in the mouse genome. Indeed, also the study
of stably transfected MCF-7 cells showed that in about
20% of the clones the expression of luciferase was
insensitive to the presence of E2.
The system generated represents a major advance-
ment for the understanding of the physiology of com-
pounds active through the ERs. In the last decade, the
ability to transfect cells in culture with reporters of ER
transcriptional activity granted a novel insight into the
complexity of estrogen action. It was shown that the
binding of the hormone-receptor complex to the spe-
cific sequences of the promoter is not sufficient to
Fig. 3. Immunohistochemical Localization of ERa and Luciferase in Uterus of E2-Treated Ovariectomized Mice
ERa was immunostained with ER antibodies in nuclei of stroma (S), lumen (E), and glandular (G) epithelium. No immunore-
activity was detected with adsorption of the preimmune serum (inset). Luciferase staining was present in the cytoplasm of cells
from stroma, myometrium, and epithelium lining glands and lumen.
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ensure the hormone-regulated transcription of the tar-
get genes. The ER must, in fact, interact with a series
of proteins modulating its transcriptional activity (22,
23). These findings were supported by crystallo-
graphic studies showing the structural conformation of
ER bound to natural or synthetic ligands (24, 25).
These and other investigations on steroid receptors
demonstrated how synthetic ligands, by inducing spe-
cific structural conformations that modify the possibil-
ities of the receptor to interact with its coregulators,
may change its transcriptional activity in a tissue-
specific fashion (10, 23, 26). In addition, several stud-
ies underlined that the binding of the specific hormone
is not indispensable to ER transcriptional activation.
Unliganded ER was shown to regulate the transcrip-
tion of target genes after activation of specific kinases
(27, 28). Finally, ER dosage may also constitute an
important element in the control of ER tissue-specific
activities.
A major challenge at present is to demonstrate how
these mechanisms are relevant in physiological sys-
tems and how ER activity is regulated in its numerous
target cells. The model generated will facilitate these
studies by providing a system in which the activity of
the receptor on ERE-containing genes can be as-
sessed in a very restricted time frame. To this aim, we
purposely made use of the natural firefly luciferase
gene, the turnover of which in mammalian cells is
about 3 h (29). By measuring the levels of luciferase
accumulation, therefore, we will be able to monitor the
state of activity of the receptor in response to the
fluctuating hormone levels during the estrous cycle or
after administration of ER ligands. In addition, these
mice will allow identification of novel tissues and cell
types targeted for the hormone in vivo in both sexes.
Further investigation is necessary to understand
whether the high content of luciferase in bone marrow,
brain, tail, tongue, or liver observed in this study
should be ascribed to the tissue characteristics facil-
itating the recovery/measurement of the luciferase en-
zymatic activity, to the low catabolism of the exoge-
nous protein, or to the activation of the unliganded
resident receptor via cross-coupling with membrane
receptors. We would rule out the possibility of lucif-
erase induction by ERR (ER-related receptor) orphan
receptors based on the observation that tissues such
as kidney and heart, known to express very high con-
centrations of ERRa and g, display a very low basal
activity of the reporter (30–32). Similarly, a more ac-
curate evaluation of the time course of E2 induction is
necessary before drawing any conclusion on the po-
tency of the hormonal treatment in the various organs.
The present study was carried out at 16 h of hormonal
treatment. It is likely that the relatively low E2-depen-
dent accumulation of luciferase that we observed in
certain organs (e.g. uterus, mammary glands) is due to
ER down-regulation, which in these organs occurs in a
few hours after E2 administration. Appropriate time-
course studies will better clarify the kinetics of ER
activity in the various tissues.
From the pharmacological point of view, the system
generated is very interesting, particularly for the iden-
tification of novel SERMs because it will identify in
which organs the molecule of interest displays full,
partial agonist, or antagonist activity. The preliminary
assessment of the activity of 4-hydroxytamoxifen in
bone marrow cells and in vivo, supports the validity of
this model in this type of studies. In previous studies,
reporter-based systems for the in vivo identification of
ligands for intracellular receptors were generated us-
ing fusion proteins between the RXR and RAR ligand
binding domain and the DNA binding domain of the
yeast protein GAL4 (33, 34). These systems were
proved to be useful for the detection of endogenous
ligands; however, because of the relevance of protein/
protein interaction in the activity of intracellular recep-
tors, GAL4-receptors fusion products might be unable
to undergo conformational changes indispensable
for the action of tissue selective synthetic ligands
(10, 23, 26).
In spite of the fact that the system generated will not
provide an insight on the exact nature of the ER acti-
vated [ERa, ERb, or other proteins not known active
through estrogen response elements (EREs)], appro-
priate breeding of the ERE transgenic mice with se-
lective ERa and -b knockout (K.O.) mice will erase this
limitation.
The transgenic mouse generated in this study can
be used to produce models for the physiological,
pharmacological, and toxicological analysis of other
intracellular receptors. In addition, because of the in-
trinsic characteristics of the reporter above specified,
Fig. 4. Expression of Luciferase in Primary Bone Marrow
Cells from Transgenic Mice
Two million bone marrow cells were suspended in phenol
red-free RPMI 1640 with 10% stripped serum. Cells were
treated with increasing concentrations of E2 (0.001, 0.01, 1.0,
and 10 nM) or with 100 nM ICI 182,780 (ICI) or 4-hydroxyta-
moxifen (T) alone or with 1 nM E2. Progesterone (Prog) and
dexametasone (Dex) were used at 10 nM final concentration.
Control cells (C) were treated with the same concentration of
ethanol present in the hormone solutions (0.0001%). Bars
represent the average 6 SEM of five individual experiments
each done in triplicate. *, P , 0.01 as compared with the
control; **, P , 0.005 as compared with the control; F, P ,
0.05 as compared with the T-treated); P values were calcu-
lated with ANOVA followed by Scheffe´ test.
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the model could be particularly suited for studying the
pharmacokinetic profile of natural and synthetic ER
ligands. Finally, these transgenic mice can be used as
biosensors to investigate whether environmental or
food pollutants act as endocrine disruptors by inter-
fering with the physiological state of ER activity.
MATERIALS AND METHODS
Plasmid Construction
Each functional cassette of the vector used for transgenesis
was flanked with unique restriction sites to facilitate further
manipulations. Each element of the construct generated was
sequentially cloned in the vector pBluescript (Stratagene, La
Jolla, CA). The basic construct without insulators was named
pERE and contains two canonical EREs (35) (ERE2X) spaced
by 8 bp, a minimal thymidine kinase (tk) promoter from herpes
simplex virus (36) (55 bp downstream from the ERE2X) and
the luciferase reporter gene (Fig. 1A). This construct was
assembled with the following components: 1) the 2,731-bp
DNA fragment encoding the luciferase excised from the
pGl2basic vector (Promega Corp., Madison, WI) with the SalI
restriction enzyme blunted and ligated into the blunted HindIII
site of pBluescript; 2) the 168-bp BamHI/XhoI fragment con-
taining the tk promoter from pBLCAT2 (37), blunted and
ligated into the blunted PstI site of the pBluescript; 3) the
82-bp XhoI/ClaI fragment containing the ERE2X excised from
pGL2basic vector (Promega Corp.) in which it has been pre-
viously cloned (see below), blunted, and ligated into the
blunted SalI site of the pBluescript.
Two tandem copies of the insulators HS4 (2.4-kb DNA
fragment) from chicken b-globin gene were obtained by di-
gesting the vector pBS(II)HS4, generously provided by S. Y.
Tsai (38), with SalI restriction enzyme; a single copy of MAR
(3-kb DNA fragment) from chicken lysozyme gene was ex-
cised with digestion of the pBSKMAR, kindly provided by L.
Hennighausen (39), by XbaI/BamHI restriction enzymes. The
insulator fragments were blunted and inserted in the blunted
KpnI and NotI sites located at the 59- and 39-end of pERE,
Fig. 5. Pharmacological Modulation of Luciferase Activity in Vivo
Luciferase activity in bone and liver of 2-month-old male mice. Upper panel, Time course experiments in animals injected s.c.
with 50 mg E2/kg; middle panel, dose dependency at 6 h treatment; lower panel, blockade of E2 activation by tamoxifen (T) and
ICI 182,780 (ICI) and partial agonist activity of T. Antagonists (250 mg/kg) were given 1 h before E2. Bars represent the average 6
SEM of five to seven mice. *, P , 0.01 as compared with the control), E, P , 0.01 as compared with the E2-treated); P values were
calculated with ANOVA followed by the Scheffe´ test.
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giving the pHS4 (EMBL accession no. AJ2777959) and pMAR
(EMBL accession no. AJ2777959) constructs.
Generation of ERE2X
The two oligonucleotides, 59-GATCCGCAGGTCACAGTGAC
CTA-39 and 59-GATCTAGGTCACTGTGACCTGCG-39, were
annealed, the resulting double strand oligo was ligated and
digested with BamHI, and the bands corresponding to mono-
mers or multimers were extracted from an acrylamide gel as
described previously (40) and ligated into the BglII site of
pGL2basic vector.
Cell Cultures and Transfections
Breast carcinoma MCF-7, neuroblastoma SK-NBE, and cer-
vix carcinoma HeLa cell lines were routinely grown in RPMI
1640 medium supplemented with 10% FBS. Stable transfec-
tions of MCF-7 cells were performed with the calcium phos-
phate procedure as previously described (41). Twenty four
hours before transfection, 1.5 3 106 cells were seeded in
Petri dishes with RPMI 1640 supplemented with 10% FCS;
6 h before addition of 1 ml CaPO4/DNA mixture the medium
was replaced with DMEM supplemented with 10% FCS. The
CaPO4/DNA mixture used for transfection contained 1 ng of
pSV2Neo plasmid expressing G418 resistance gene (CLON-
TECH Laboratories, Inc., Palo Alto, CA; GenBank accession
no. U02434) together with 10 mg of the pERE, pHS4, or pMAR
vectors and 9 mg salmon sperm DNA. Forty eight hours after
transfection, 300 mg/ml G418 (Life Technologies, Inc.) were
added to the culture medium. Medium and selective agents
were replaced three times a week. After 21 days selection, 48
clones for each transfection were isolated with cloning rings
and expanded. To test the expression of luciferase, each
clone was grown in RPMI 1640 without phenol red and sup-
plemented with 10% dextran charcoal-stripped FBS (DCC-
FBS) (41) for at least 1 week before 16 h induction with E2 (1
nM in 0.00001% ethanol). Control cells were treated for 24 h
with 0.00001% ethanol. Protein extracts were obtained as
previously described (27), and the enzymatic assay was car-
ried out as described in detail below.
Transgenic Mice
For microinjection, linearized pMAR and pHS4 constructs
depleted of plasmid sequences were obtained with BsshII
restriction enzyme digestion. With these vectors two different
types of transgenic mice were produced by pronuclear DNA
injection of zygotes C57Bl/6xDBA/2, F2 generation, using
standard procedures (17). Injected zygotes were reimplanted
into pseudopregnant B6D2F1 (C57Bl/6xDBA/2) foster moth-
ers to complete their development. Genomic DNA was ex-
tracted as previously described (42) from tail biopsies and
used for genotyping. Briefly, tissues were lysed by addition of
1% SDS, 50 mM Tris-HCl, pH 8, and 200 mg/ml Proteinase K
and incubation overnight at 37 C; DNA was then purified by
phenol extraction and ethanol precipitation. DNAs from the
founders and their littermates were screened by PCR analy-
sis. PCR amplification was carried out in a buffer containing
10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
deoxynucleotide triphosphates, 0.25 mM of each primer, and
2 U of TAQ polymerase for 1 mg genomic DNA template. The
primers used were 59-GGCAGAAGCTATGAAACGAT-39 and
59-CGACTGAAATCCCTGGTAAT-39; after 30 cycles (30 sec
at 95 C, 30 sec at 55 C, and 30 sec at 72 C) the products were
analyzed on 2.5% agarose gels stained with ethidium bro-
mide. At the third week of age, all the potential founders
obtained from pHS4 and pMAR microinjection were screened
by PCR. From the pMAR and pHS4 groups, 10 and 7 indi-
viduals, respectively, were identified as positives for the pres-
ence of the transgene. For the experiments we used het-
erozygous littermates obtained by mating our founders with
B6D2F1 wild-type mice.
Heterozygous female mice (2 months old) were ovariecto-
mized and after 2 weeks injected s.c. with 50 mg E2/kg or with
vehicle (vegetable oil) as control. Sixteen hours later the
animals were killed, and the tissues were dissected and
immediately frozen on dry ice. For the in vivo pharmacolog-
ical studies with ER antagonists, 2-month-old heterozygous
male mice were treated by s.c. injections of the different
compounds dissolved in vegetable oil. Tissue extracts were
prepared by homogenization in 500 ml of 100 mM KPO4 lysis
buffer (pH 7.8) containing 1 mM dithiothreitol, 4 mM EGTA, 4
mM EDTA, 0.7 mM phenylmethylsulfonyl fluoride, three cycles
of freezing-thawing, and 30 min of microfuge centrifugation
at maximum speed. Supernatants, containing luciferase,
were collected and protein concentration was determined by
Bradford’s assay (43).
Luciferase Enzymatic Assay
Luciferase enzymatic activity in the cell and tissue extracts
was measured by a commercial kit (luciferase assay system,
Promega Corp.) according to the supplier indications. The
light intensity was measured with a luminometer (Lumat LB
9501/16, Berthold, Wildbad, Germany) over 10 sec and ex-
pressed as relative light units (RLU) over 10 sec/mg proteins.
Immunohistochemistry
Uteri of ovariectomized mice, treated as before, were dis-
sected and fixed through immersion in 4% paraformaldehyde
in 0.1 M phosphate buffer pH 7.2 (PB), for 5 h. Tissues were
dehydrated with an ascending ethanol scale, clarified with
xylene, and processed for paraffin embedding. Serial 4 mm
microtome sections were cut and collected onto slides
coated with poly-L-lysine (Sigma, St. Louis, MO). After 16 h
drying at 37 C, sections were hydrated through a descending
ethanol scale and boiled in 10 mM citrate buffer (pH 6.0) for 15
min in a microwave oven, washed for 10 min with PBS, and
then processed for luciferase and ERa immunodetection at
room temperature. Sections were first incubated for 30 min
with 0.3% H2O2 to quench endogenous peroxidase activity
and subsequently washed three times with PBS for 10 min.
After saturation with 10% preimmune goat serum supple-
mented with 0.3% Tween 20 (Sigma), sections were incu-
bated with the antiluciferase (Sigma, 1:1800 dilution in PBS
with 10% goat serum and 0.3% Tween 20) or anti-ERa (kindly
provided by J. Green, 5 mg/ml in 10% goat serum and 0.3%
Tween 20) polyclonal antibodies for 16 h, washed with PBS
(six times, 10 min each), incubated for 60 min with an anti-
rabbit secondary antibody (raised in goat, 1:200 dilution in
PBS supplemented by 1% goat serum and 0.3% Tween 20;
Vector Laboratories, Inc., Burlingame, CA) and then washed
again (six times with PBS, 10 min each). Antibody-antigen
detection was obtained by 40 min incubation with avidin-
biotin-horseradish peroxidase (HRP) from an ABC kit (Vector
Laboratories, Inc.). Immunostaining was visualized by expo-
sure to HRP substrate 3,39-diaminobenzidine (DAB Fast,
Tablet Set, Sigma). After one wash in PBS and few tap water
changes, sections were allowed to air dry and then covered.
Pictures were taken with a digital camera (Coolpix 990; Ni-
kon, Melville, NY) applied to a Axioscope microscope (Carl
Zeiss, Thornwood, NY).
Primary Bone Marrow Culture
After mice were killed, bone marrow cells were flushed out
from femur and tibia of ovariectomized animals, using a sy-
ringe filled with PBS. Cells were collected in a 15 ml Falcon
tube (Becton Dickinson and Co., Meylan Cedex, France) and
washed once with PBS. After centrifugation the cell pellet
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was resuspended in RPMI 1640 supplemented with 10%
DCC-FBS; cells were counted and plated in a six-well dish
(2 3 106cells per well). For the treatment, all compounds were
dissolved in ethanol and added to the medium at the indi-
cated concentration. After 16 h the cells were collected in
Eppendorf tubes, washed once with PBS, re-suspended in
100 ml KPO4 lysis buffer (as above), and frozen and thawed
three times. After 30 min microfuge centrifugation at maxi-
mum speed, supernatants were collected for the determina-
tion of protein concentration and luciferase activity.
Experimental Animals
Animal experiments performed in this study were conducted
according to the “Guidelines for Care and Use of Experimen-
tal Animals.”
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Erratum
In the article “Pleiotropic Effects of Substitutions of a Highly Conserved Leucine Residue
in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with
Respect to Constitutive Activation and Hormone Responsiveness” by Hiromitsu Shinozaki,
Francesca Fanelli, Xuebo Liu, Julie Jaquette, Kazuto Nakamura, and Deborah L. Segaloff
(Molecular Endocrinology 15: 972–984, 2001), The heading for the right column of Table 1
should read “125I-hCG Bound (ng/106 cells)”, not “Kd (nM)”.
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